El-Farrash Mohamed A, Youssef Jilan M, El-Mongy Shaymaa E
Department of Medical Microbiology & Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
J Med Dent Sci. 2003 Jun;50(2):147-54.
Recurrent herpes labialis (RHL) occurs in up to 40% of the population. Although the disease is usually self-limiting, patients seek treatment because of the significant pain and visibility of the lesion. Xanthine oxidase inhibitors (XOI) have been reported to have a potent antiviral effect against influenza-A virus. We examined the effect of the systemic xanthine oxidase inhibitor, allopurinol, on RHL duration of illness, severity of symptoms, number and frequency of recurrence during a 4-year follow up period in Egyptian patients. Duration of illness was shortened by about 25%, early disappearance of pain and other symptoms occurred. Also, aborted episodes were noticed when allopurinol was given just after beginning of common colds, at the prodromal stage of RHL or during severe stress conditions. Patients receiving 3 courses of treatment had markedly decreased recurrences during the follow up period. Ex vivo experiments to examine virus-induced plaque formation on Vero cells in the absence or presence of different concentrations of the drug could not prove any direct anti herpetic effect of the drug. However, allopurinol seems to be safe and effective in reducing duration of RHL and to abort lesion or prevent its appearance in treated patients even when they experience immunosuppressive conditions.
复发性唇疱疹（RHL）在高达40%的人群中出现。尽管该病通常为自限性，但患者因病变引起的剧痛和明显可见性而寻求治疗。据报道，黄嘌呤氧化酶抑制剂（XOI）对甲型流感病毒具有强大的抗病毒作用。我们在埃及患者的4年随访期内，研究了全身性黄嘌呤氧化酶抑制剂别嘌醇对RHL病程、症状严重程度、复发次数和频率的影响。病程缩短了约25%，疼痛和其他症状提前消失。此外，在普通感冒刚开始、RHL前驱期或严重应激状态下给予别嘌醇时，可观察到发作中止。接受3个疗程治疗的患者在随访期内复发明显减少。在有无不同浓度药物的情况下，检测病毒在Vero细胞上诱导噬斑形成的体外实验未能证明该药物有任何直接的抗疱疹作用。然而，别嘌醇在缩短RHL病程以及使治疗患者的病变中止或预防其出现方面似乎是安全有效的，即使这些患者处于免疫抑制状态。
